International Journal of Advances in Engineering and Management (IJAEM)
Volume 3, Issue 7 July 2021, pp: 1442-1451 www.ijaem.net ISSN: 2395-5252

Renal Impact on Rheumatoid Arthritis: A Review

Sayan Bhattacharjee[*1],SouvikBiswas[*2],Arijit Das[*3],Abhijit Ghosh[*4], Nitish Majhi[*5],Sourin Mondal[*6].
[1,4,5,6] 4th Year Student OfBharat Technology, Banitabla, Uluberia, Howrah Pin-711316
[2,3] Assistant Professor Of Bharat Technology

Submitted: 25-06-2021 Revised: 06-07-2021 Accepted: 09-07-2021

ABSTRACT : Biological therapies that concentrate on infective cytokines like TNF, IL-1b or IL-6 have greatly improved thetreatment of RA. sadly, not all RA patients reply to current biological therapies and responsesare not invariably maintained, suggesting that there ar various drivers of RA pathologic process that mayserve as promising therapeutic targets. Discovery of the new Th17 set of Th cells, and their role inautoimmune disease development, has concerned the unhealthy IL-12 and IL-17 families of cytokines in RA sickness pathologic process. Members of those protein families ar elevated within the blood and joints of RA patients and are shown to stay elevated in patients WHO don't reply to currentbiologics. additionally, these cytokines are shown to play roles in joint destruction and erosion. A new taxon of biologics that concentrate on the IL-12 and/or IL-17 signalling pathways ar below development.Here we tend to review proof for a task of Th17 cells also as IL-12 and IL-17 cytokines in RA pathologic processas the explanation for a ensuant discussion of the continued and completed clinical trials of new risingbiologic therapies directed at IL-12 or IL-17 pathway inhibition.

Key words:
Biologic, Th17 cell, IL-17, IL-17A, IL-12, IL-23, rheumatoid arthritis, autoimmune disease, inflammation,synovitis.

I. INTRODUCTION:

A chronic inflammatory disorder moving several joints, together with those within the hands and feet.In atrophic arthritis, the body's system attacks its own tissue, together with joints. In severe cases, it attacks internal organs. [1]

Rheumatoid arthritis affects joint linings, inflicting painful swelling. Over long periods of your time, the inflammation related to atrophic arthritis will cause bone erosion and joint deformity. [2]

While there isn't any cure for atrophic arthritis, physiatrics and drugs will facilitate slow the disease's progression. Most cases may be managed with a category of medicines referred to as anti-rheumatic medication (DMARDS). [3, 4]

People may experience:
Pain areas: in the joints, back, or muscles
Joints: stiffness, swelling, tenderness, or weakness.
Whole body: fatigue, anaemia, or malaise.
Skin: lumps or redness.
Hand: bump on the finger or swelling.
Also common: flare, dry mouth, physical deformity.[5]

Abreviations:
RA – Rheumatoid Arthritis
WHO- World Health Organisation
IL- Inter Leukin
DMARDs - Disease-modifying antirheumatic drugs
CD4+-Cluster Of Differentiation 4
TNF – Tumor necrosis factor
NK- Natural Killer Cells
Csa- Cell Surface Antigen
NSAIDs - Non-steroidal anti-inflammatory drugs

PATHOPHYSIOLOGY OF RHEUMATOID ARTHRITIS

Function and interplay of CD4+ T cell subsets Th1/Th2 paradigm

Although associate oversimplification, the Th1/Th2 paradigm remains a helpful construct to know progression on the road of T cell differentiation [6,7]. beneath the combined influence of nerve fiber cells, matter stimulation and also the native protein environment, naive CD4+ T cells differentiate into distinct Th cell subsets with specific effector functions characterised by the cytokines made (Fig. 1). Differentiation of naive CD4+ T cells into Th1 cells that secrete IFN-g and participate in host defence against living thing pathogens is regulated by the protein IL-12 [8, 9].

Th1 cells were originally thought to play a job within the genesis of disease as a result of IL-

International Journal of Advances in Engineering and Management (IJAEM)
Volume 3, Issue 7 July 2021, pp: 1442-1451 www.ijaem.net ISSN: 2395-5252

12 and IFN-g area unit extremely expressed at sites of inflammation [9, 10]. In RA, as an example, elevated levels of IL-12 are known in each body fluid and secretion of a considerable portion of patients and related with inflated malady activity [11]. IL-12 has been shown to be expressed in arthritic secretion tissue, largely by CD68+ cells within the secretion sublining, and to stimulate IFN-g production by infiltrating T cells [10, 12, 13].

IL-12 and IL-23 and their receptors

IL-12 is a heterodimeric cytokine composed of two disulphide-linked subunits of molecular weights 35 and 40 kDa (p35 and p40) and is produced by cells of the innate immune system as well as by B cells [14,15]. The IL-12 p40 subunit is shared with another structurally related heterodimeric cytokine, IL-23, which is mainly secreted by activated macrophages, dendritic cells and monocytes. In addition to the p40 subunit shared with IL-12, IL-23 is also composed of a p19 subunit[16]. Both IL-12 and IL-23 interact with heterodimeric receptors that share a common IL-12Rb1 subunit, to which the p40 subunit is thought to bind. The biological specificities of IL-12 and IL-23 reflect binding of IL-12 p35 to its receptor's IL-12Rb2 subunit and IL-23 p19 to its IL-23R subunit [17].

IL-17A and its receptors

Th17 cells manufacture the unhealthy protein IL-17A and lots of of the inflammatory activities in autoimmune disorder are attributed to the present protein. IL-17A, a a hundred and fifty five aminoalkanoic acid, 15-kDa compound protein, could be a member of a singular protein family comprising 5 alternative members (designated IL-17B through IL-17F). Th17 cells manufacture IL-17A and IL-17F, every as disulphide-linked homodimers, however IL-17A_IL-17F heterodimers have additionally been detected [18]. each IL-17A and IL-17F activate a heterodimeric receptor advanced composed of IL-17RA and IL-17RC supermolecule subunits. IL-17F is a smaller amount potent than IL-17A in rheumy synoviocytes and regulates unhealthy organic phenomenon by the same, however not identical, signalling pathway downstream of IL-17RA and IL-17RC [19].

IL-17A expression in RA

High concentrations of IL-17A in blood and synovia square measure related to sickness severity in RA and with sickness markers like anti-citrullinated supermolecule (CCP) antibodies, suggesting elevated IL-17A signifies a a lot of severe clinical course in RA [20,21]. A longitudinal study of 2 freelance cohorts of RA patients treated with anti-TNF biologics found high baseline current Th17 cell levels correlate with a scarcity of response to anti-TNF medical aid [22]. Peripheral blood cells from nonresponder atient's incontestable accumulated excited IL-17 production compared with communicator patients. These findings recommend that incomplete responses to tumor necrosis factor blockade in patients with inflammatory inflammatory disease go together with the Th17 cells and IL-17 pathways. Early studies showed that secretion explants from RA patients, however not OA patients, created IL-17A ex vivo, as measured by bioassay [23,24]. Immunostaining unconcealed that cells secreting IL-17A were localized to T cell_rich areas of the membrane. though Th17 cells square measure a outstanding supply of IL-17A, different cell varieties may turn out IL-17A, as well as CD8+ T cells, gd T cells, NK T cells, NK cells, neutrophils, macrophages, eosinophils and mast cells [25]. so IL-17A found within the rheumatic joint is also derived from a large vary of cells within the accommodative and innate immune systems.[26]

International Journal of Advances in Engineering and Management (IJAEM)
Volume 3, Issue 7 July 2021, pp: 1442-1451 www.ijaem.net ISSN: 2395-5252



Fig :Differentiation pathways of t helper cells

II. MATERIAL AND METHODS

Clinical. Most patients were admitted to hospital for study from the inflammatory disease Clinic of the University of Illinois Hospitals; a couple of were studied in different hospitals. In all, forty one patients were investigated. The identification of autoimmune disorder was created exploitation the standards of the yank Rheumatism Association[27]. None had Marie-Strumpell disease. The patients weren't designated haphazardly. several we re designated due to long-standing severe autoimmune disorder with marked deformities. Some patients were chosen for study as a result of albuminuria liad been found on routine qualitative analysis within the patient clinic, et al. as a result of that they had been treated with gold salts[28]. In fact, the patients were designated for nephritic diagnostic test as a result of it had been thought that they were the patients possibly to own nephritic abnormalities. Tha average period of autoimmune disorder was over eight years (range: a pair of months to twenty five years). Eighteen patients had been treated with gold salts for periods of twelve weeks to over four years; 13 had received a minimum of one g. of Myochrisine. Twenty-one had received corticotrophin or Hydrocortone and its analogs. Most patients had been treated with thirty seven.5 to 75 mg. of Hydrocortone daily or its equivalent. Eight had been treated with each gold salts and corticotrophin or Hydrocortone. Eleven had received neither drug[29,30]. Measurements of nephritic functions. The ways used for the measuring of nephritic functions and for qualitative analysis are delineated elsewhere[31].

The ways wont to get specimens of nephritic tissue by body covering biopsy are delineated , as have the ways of handling the nephritic tissue. wherever indicated, sections stained with acid-base indicator and vermifuge were examined for ainyloiddeposits[32].

Investigating centers at that biopsies were taken for inclusion within the written account were in Scandinavian country, Canada, Netherlands, and European nation, playing sixteen,9,11, and twenty four biopsies, severally. knowledge on second biopsies were collected from studies in Scandinavian country and European nation. all told cases, except one early patient from the Norwegian center, the nephritic diagnostic test was performed to confirm the protection of maintaining the patient on CSA medical aid. This was either undertaken as a part of the study protocol once patients had completed the initial 6-12-month treatment amount and in agreement to long maintenance (Norway and Canada), or was initiated regionally for those patients UN agency had been effectively treated for long periods of your time (The European country and Switzerland) [33].

Apart from nephritic morphology, different knowledge co

International Journal of Advances in Engineering and Management (IJAEM)
Volume 3, Issue 7 July 2021, pp: 1442-1451 www.ijaem.net ISSN: 2395-5252

llected from patients undergoing diagnostic test enclosed age, sex, weight, force per unit area, dosage, duration, and temporal order of CSA medical aid, assessment of nephritic perform (as determined by humor creatinine levels), and use of concomitant medication (corticosteroids, nonsteroidal antiinflammatory medicine [NSAIDs], and medication agents)[34].

TREATMENT PROTOCOLS

The treatment protocols of the studies from that the patients were derived applied slightly totally different dosing rules for the utilization of CSA. The beginning doses for patients within the Norwegian and Swiss studies ranged from three.2mg/kg/day to six.6 mgkglday, aside from one patient, UN agency started at ten mg/kg/day. Patients within the Canadian and Dutch studies received lower doses, beginning at a mean of two.6 mgkg/day. Some patients from country study received intermittent CSA medical care in line with a hard and fast schedule. indefinite quantity changes were typically created by titrating up or down, dependening on effectuality and tolerability[35,36].

RENAL BIOPSY EVALUATION

Biopsy samples were obtained from the study locations and delivered for central review by the medical specialist engaged within the review of all diagnostic test specimens within the register, together with management samples (M. J. Mihatsch, Institute of Pathology, Basel, Switzerland). This medical specialist was blind to all or any clinical and laboratory knowledge, together with whether or not the patient had received CSA. His assessment was ultimately wont to reason the diagnostic test features[37].

III. RESULTS

No microscopic anatomy abnormality was detected within the kidneys of twenty one patients. Arterio-
and sclerosis or artery nephropathy were the foremost common microscopic
anatomy abnormalities, and were determined in fourteen biopsies. In most patients these lesions were comparatively delicate. the typical age of the patients with vascular changes was fifty years; that of these with traditional kidneys was thirty seven years. [38,39].

Amyloidosis was found within the kidneys of 4 patients, 3 of whom were being treated with hydrocortisone. Lupus Bright's disease was diagnosed in 2. alternative proof of general autoimmune disease was later on incontestable in each patients with lupus Bright's disease. Glomerulitis of the kind represented in rhcumatoid inflammatory disease by Baggenstoss and Rosenbergl and by Fingerman and Andrus2 wasn't determined [40].

CLINICAL MANIFESTATIONS, DIAGNOSIS AND THERAPY

It is vital to recollect that not like the response of neutrophillsto microorganism incoming in a very joint by haematogenous unfold, as an example, the initiation of the cellular immune reaction in stage one of atrophic arthritis doesn't manufacture symptoms in and of itself. Patients area unit unlikely to possess symptoms in these early events of immune recognition. The symptoms of atrophic arthritis begin only if the assembly and unleash of cytokines by macrophages and activated t-lymphocytes occur growth begin within the dropsical synovium and neutrophils area unit drawn to joint cavity[41].

STAGES 2 AND 3

The second and third stages of autoimmune disorder area unit similar in nature and dissent primarily in their severity and amplitude. the results of various parts of inflammation and proliferation within the creaky joint area unit additive, however they need to be studied singly despite the fact that they're activated at the same time [42,43].

PATHOPHYSIOLOGY

The reaction becomes unionized within the perivascular areas within the membrane because the increase in variety of T cells results in the proliferation and differentiation of B cells and to the assembly of antibodies at intervals an increasing scaffold of recent blood vessels and secretion cell proliferation[44].

ANGIOGENESIS

The development of an extensive network of new blood vessels in the synovial membrane is essential to the evolution of rheumatoid synovitis. Macrophages from rheumatoid synovial tissue can induce the formation of new blood vessels, and this induction appears to be mediated by cytokines (Class I and Class II heparin-binding growth factor)

International Journal of Advances in Engineering and Management (IJAEM)
Volume 3, Issue 7 July 2021, pp: 1442-1451 www.ijaem.net ISSN: 2395-5252

that manifest site direct specificity. Once activated to proliferate, endothelial cells fashion themselves into blood-carrying tubes and express plasminogen activator metaloproteinases that facilitate their invasiom of connective tissue to deliver nutrients to proliferating cells[45].

STAGE 4

The irreversible destruction of cartilage occurs in stage 4 of the disease. It begins when the proliferating synovial membrane becomes organised in an invasive front that invades cartilage, tendons, and subchrondal bone. At the same time, it is most difficult stage to diagnose and monitor; inexpensive, sensitive assays or imaging techniques are simply not available to detect this early loss of crucial connective tissue[46].

CLINICAL MANIFESTATIONS

Rheumatoid arthritis generally become symptomatic gradually. The metacarpophalangeal joints, proximal interphalangeal joints, and wrists are the first to become symptomatic. The hip and ankles are rarely effected early in the course of rheumatoid arthritis. General fatigue and malaise may be present before joint symptoms are probably generated by cytokines such as tumor necrosis factor and interleukin-1.motning stiffness, a sensitive but nonspecific symptom of rheumatoid arthritis, is generated by an increase in extracellular fluid in and around the joint[47]. The joints are warm, but because synovial vessels, not superficiall vessels, are dilated and proliferative, the skin is very red. When joints develop effusions, the patient hold them flexed at 5 to 20 degrees; indeed, it is often too painful to extend them fully. In stage 2 of the disease extraarticular manifestations, such as rheumatoid nodules, vasculities, or neuropathy are rare. Similarly, Sjogren's and Felty's syndromes rarely seen[48].

DIAGNOSIS :

A careful history-taking and physical examination are essential for making the diagnosis of rheumatoid arthritis. The most frequent confounding diagnosis include other diffusive connective-tissue diseases such as systematic lupus erythematosus , scleroderma and dermatomyositis, but these are generally excluded or identified on the basis of the history and physical examination as well[49]. The seronegative spondyloarthropathies , including syrotic arthritis, Reiter's syndrome, ankylosing spondylitis, and the arthritis of chronic inflammatory bowel disease, are thr second most frequent confounders; these frequently effect the back and large joints in an asymmetric fashion. When confronted with an individual patient, the physician can rely on the American Rheumatism Association criterion that symptoms be prenst for at least six weeks. Rarely, polyarticular crystal deposition disease, polyarticular septic arthritis, and a host of very unusual entities may be confused with a rheumatoid arthritis[50].

Laboratory tests alone cannot be used to make a conclusive diagnosis of rheumatoid arthritis, particularly early in the course of the disease. A nonspecific decrease in the haemoglobin level(rarely to less than 10 g per decilitre) accompanies a variable elevation in the erythrocyte sedimentation rate (Western method). Quantitative measurement of C-reaction protein will show a pattern parallel to that of the erythrocyte sedimentation rate, and the pattern may correlate with the appearance of the destructive lessons in the stage 4 of the disease. Biosynthesis of these acute-phase reactants is induced by interlukin-6. Eosinophilia and thrombocytosis often accompany active disease, as does a mild elevation of the numbers of circulating neutrophils. Elevation in the concentration of serum cryglobulins and precipitating antibodies to soluble cellular antigens are reported to correlate with extraarticular disease[51].

STAGE 5

It has been the premise of this review that by the time rheumatoid arthritis has reached stage 5 irreversible destruction of cartilage is well under way, and attempts to protect joints from progressive destruction are futile. I believe that aggressive therapy with cytotoxic drugs or even more specific compounds generated by recombinant technology will have little potential benefit with patients with stage 5 disease. Systemic vasculities in patients with stage 5 disease must be treated appropriately with glucocorticoids, cytotoxic drugs, it is appropriate not to overtreat. Physical therapy, occupational therapy, and reconstructive joint surgery will give the best functional results[52].

RENAL ARTHRITIS

NECROPSY AND RENAL TISSUE REVIEW

General arteriosclerosis was observed at necropsy in 77 patients (58%); 49 (37%) showed recent or scarred infarction of one or more organs. Macroscopic abnormalities were found in the kidneys of 43 patients (33%) [53].

International Journal of Advances in Engineering and Management (IJAEM)
Volume 3, Issue 7 July 2021, pp: 1442-1451 www.ijaem.net ISSN: 2395-5252

RENAL AMYLOIDOSIS

Renal amyloidosis was found in 14 patients (11%);there were no cases of amyloidosis without renal involvement. One case showed concomitant focal glomerulonephritis; another showed concomitant systemic vasculitis without renal involvement[54].

RENAL VASCULITIS

Renal vasculitis was found in eight out of a total of 18 cases with systemic vasculitis at necropsy. Among these eight patients the glomeruli showed severe proliferative glomerulonephritis in four and non-specific changes in one; the large renal vessels were normal in the other 10. Two of these 10 patients, however, had membranous glomerulopathy, two had nonspecific glomerular abnormalities, and one had amyloidosis[55].

GLOMERULAR LESIONS

Glomerular lesions were found in 57 patients (43%), with specific changes in 26 of them. Proliferative glomerulonephritis occurred in I1 patients: six had accompanying systemic vasculitis (see above). In these six, inflammation was severe, with extracapillary glomerulonephritis in four and diffuseproliferative glomerulonephritis in two. In the five patients with proliferative glomerulonephritis but without systemic vasculitis, only one had diffuse glomerulonephritis, and four showed local focal glomerulonephritis[56].

Membranous glomerulopathy was observed in nine patients; in two, systemic vasculitis was found at necropsy as well, but without evidence of renal involvement. Focal glomerulosclerosis was noted in five patients (with concomitant amyloidosis in one), and membranoproliferative glomerulonephritis in one. Lesions of tubuli and interstitium Specific lesions of tubuli and interstitium were scarce; there were three patients with tubulointerstitial nephritis, and two with acute tubular necrosis[57,58].

DMARDS

DMARDs can be biologic or nonbiologic .23 Biologic agents include monoclonal antibodies and recombinant receptors to block cytokines that promote the inflammatory cascade responsible for RA symptoms. Methotrexate is recommended as the first-line treatment in patients with active RA, unless contraindicated or not tolerated.21 Leflunomide (Arava) may be used as an alternative to methotrexate, although gastrointestinal adverse effects are more common. Sulfasalazine (Azulfidine) or hydroxychloroquine (Plaquenil) is recommended as monotherapy in patients with low disease[59].

NSAIDS AND CORTICOSTEROIDS

Drug therapy for RA may involve NSAIDs and oral, intramuscular, or intra-articular corticosteroids for controlling pain and inflammation. Ideally, NSAIDs and corticosteroids are used only for short-term management. DMARDs are the preferred therapy[60].

TREATMENT

After RA has been diagnosed and an initial evaluation performed, treatment should begin. Recent guidelines have addressed the management of RA,21,22 but patient preference also plays an important role. There are special considerations for women of childbearing age because many medications have deleterious effects on pregnancy. Goals of therapy include minimizing joint pain and swelling, preventing deformity (such as ulnar deviation) and radiographic damage (such as erosions), maintaining quality of life (personal and work), and controlling extra-articular manifestations. Disease-modifying antirheumatic drugs (DMARDs) are the mainstay of RA therapy[61].

DURATION OF TREATMENT

Remission is obtainable in 10 to 50 percent of patients with RA, depending on how remission is defined and the intensity of therapy.Remission is more likely in males, nonsmokers, persons younger than 40 years, and in those with late-onset disease (patients older than 65 years), with shorter duration of disease, with milder disease activity, without elevated acute phase reactants, and without positive rheumatoid factor or anti-citrullinated protein antibody findings.

After the disease is controlled, medication dosages may be cautiously decreased to the minimum amount necessary. Patients will require frequent monitoring to ensure stable symptoms, and prompt increase in medication is recommended with disease flare-ups[61,62].

EXERCISE AND PHYSICAL THERAPY

Results of randomized controlled trials support physical exercise to improve quality of life and muscle strength in patients with RA.Exercise training programs have not been shown to have deleterious effects on RA disease activity, pain scores, or radiographic joint damage.34 Tai chi has been shown to improve ankle range of motion in persons with RA, although randomized trials are

limited.Randomized controlled trials of Iyengar yoga in young adults with RA are underway[63].

JOINT REPLACEMENT

Joint replacement is indicated when there is severe joint damage and unsatisfactory control of symptoms with medical management. Long-term outcomes are good, with only 4 to 13 percent of large joint replacements requiring revision within 10 years. The hip and knee are the most commonly spaced joints[64,65].

IV. CONCLUSION

The activation of a cellular immune response in the genuinely susceptible host marks the beginning of the rheumatoid arthritis. The cause of the disease remains unknown, but it may due to a single virus or several viruses that generate immune responses or cross react with host tissues. The ensuring proliferation of polyclonal B lymphocytes is centered in a proliferative synovitis. Cytokines drive the proliferation of synovial cells, which ultimately amass to invade and destroy articular cartilage.

We have underestimated the morbidity and mortality of rheumatoid arthritis. Our goal must be to intervene with focused but less toxic drugs as early as feasible in the disease process.

REFERENCES:

[1]. Horton S, Walsh C, Emery P. Established rheumatoid arthritis: rationale for best practice: physicians' perspective of how to realize tight control in clinical practice. Best Pract Res Clin Rheumatol2011;25:509_21.

[2]. Mewar D, Wilson AG. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacology 2011;162:785_91.

[3]. Burmester GR, Blanco R, Charles-Schoeman Cetal.Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451_60.

[4]. Mosmann TR, Cherwinski H, Bond MW et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348_57.

[5]. McInnes I, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205_19.

[6]. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123_32.

[7]. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133_41.

[8]. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888_98.

[9]. Paunovic V, Carroll HP, Vandenbroeck K et al. Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity. Rheumatology 2008;47:771_6.

[10]. Kim W, Min S, Cho M et al. The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). Clin Exp Immunol 2000;119:175_81.

[11]. Morita Y, Yamamura M, Nishida K et al. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum 1998;41:306_14

[12]. Catalan D, Aravena O, Sabugo F, et al. B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by antitumor necrosis factor therapy. Arthritis Res Ther 2010; 12:R68.

[13]. Turrel-Davin F, Tournadre A, Pachot A, et al. FoxO3a involved in neutrophil and T cell survival is overexpressed in rheumatoid blood and synovial tissue. Ann Rheum Dis 2010; 69:755–760.

[14]. Azuma T, Zhu G, Xu H, et al. Potential role of decoy B7–H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data. PLoS Med 2009; 6:e1000166.

[15]. Hsu L-Y, Tan YX, Xiao Z, et al. A hypomorphic allele of ZAP-70 reveals adistinct thymic threshold for autoimmune disease versus autoimmune reactivity.J Exp Med 2009; 206:2527–2541.

[16]. Zanin-Zhorov A, Ding Y, Kumari S, et al. Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science 2010; 328:372–376.

[17]. Schmutz C, Cartwright A, Williams H, et al. Monocytes/macrophages express chemokine receptor CCR9 in rheumatoid arthritis and CCL25 stimulates their differentiation. Arthritis Res Ther 2010; 12:R161.

[18]. Chen G, Zhang X, Li R, et al. Role of osteopontin in synovial Th17 differentiation

in rheumatoid arthritis. Arthritis Rheum 2010; 62:2900–2908.

[19]. Church L, Filer A, Hidalgo E, et al. Rheumatoid synovial fluid interleukin-17-producing CD4 T cells have abundant tumor necrosis factor-alpha coexpression,but little interleukin-22 and interleukin-23R expression. Arthritis Res Ther 2010; 12:R184.

[20]. Hueber AJ, Asquith DL, Miller AM, et al. Cutting edge: mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010; 184:3336–3340.

[21]. Sandhya P, Danda D, Sharma D et al (2016) Does the buck stop with the bugs?: an overview of microbial dysbiosis in rheumatoid arthritis. Int J Rheum Dis 19(1):8–20. doi:10.1111/1756-185x.12728

[22]. Lundberg K, Kinloch A, Fisher BA et al (2008) Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 58(10):3009–3019. doi:10.1002/art.23936

[23]. Farquharson D, Butcher JP, Culshaw S (2012) Periodontitis, Porphyromonas, and the pathogenesis of rheumatoid arthritis. Mucosal Immunol 5(2):112–120. doi:10.1038/mi.2011.66

[24]. Konig MF, Abusleme L, Reinholdt J et al (2016) Aggregatibacteractinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci Transl Med 8(369):369ra176. doi:10.1126/scitranslmed.aaj1921

[25]. Schellekens GA, de Jong BA, van den Hoogen FH et al (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101(1):273–281. doi:10.1172/jci1316

[26]. Schellekens GA, Visser H, de Jong BA et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43(1):155–163. doi:10.1002/1529-0131(200001)43:1<155::aid-anr20>3.0.co;2-3

[27]. van der Helm-vanMilAH, Verpoort KN, Breedveld FC et al (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7(5):R949–R958. doi:10.1186/ar1767

[28]. Nordberg LB, Lillegraven S, Lie E et al (2017) Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD naive patients classified according to the 2010 ACR/EULAR criteria. Ann Rheum Dis 76(2):341–345. doi:10.1136/annrheumdis-2015-208873

[29]. Derksen VF, Ajeganova S, Trouw LA et al (2016) Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present. Ann Rheum Dis 76(4):716–720. doi:10.1136/annrheumdis-2016-209794

[30]. Verpoort KN, Jol-van der ZijdeCM, Papendrecht-van der Voort EA et al (2006) Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 54(12):3799–3808. doi:10.1002/art.22279.

[31]. van Beers JJ, Schwarte CM, Stammen-Vogelzangs J et al (2013)The rheumatoid arthritis synovial fluid citrullinome reveals novelcitrullinated epitopes in apolipoprotein E, myeloid nuclear differentiationantigen, and beta-actin. Arthritis Rheum 65(1):69–80. doi:10.1002/art.37720

[32]. Kuhn KA, Kulik L, Tomooka B et al (2006) Antibodies againstcitrullinated proteins enhance tissue injury in experimental autoimmunearthritis. J Clin Invest 116(4):961–973. doi:10.1172/jci25422

[33]. Scherer HU, van der Woude D, Ioan-Facsinay A et al (2010)Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 62(6):1620–1629. doi:10.1002/art.27414

[34]. Harre U, Lang SC, Pfeifle R et al (2015) Glycosylation of immunoglobulinG determines osteoclast differentiation and bone loss.Nat Commun 6:6651. doi:10.1038/ncomms7651

[35]. Hafkenscheid L, Bondt A, Scherer HU et al (2017) Structural analysisof variable domain glycosylation of anti-citrullinated proteinantibodies in rheumatoid arthritis reveals the presence of highlysialylated glycans. Mol Cell Proteomics 16(2):278–287. doi:10.1074/mcp.M116.062919

[36]. Wang Z, Nicholls SJ, Rodriguez ER et al (2007) Proteincarbamylation links inflammation, smoking, uremia and

atherogenesis. Nat Med 13(10):1176–1184. doi:10.1038/nm1637

[37]. Verheul MK, van Erp SJ, van der Woude D et al (2016) Anticarbamylatedprotein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhancedcarbamylation; renal failure, smoking and chronic inflammation. Ann Rheum Dis 75(8):1575–1576. doi:10.1136/annrheumdis-2016-209248

[38]. Ospelt C, Bang H, Feist E et al (2017) Carbamylation of vimentin isinducible by smoking and represents an independent autoantigen inrheumatoid arthritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2016-210059 Published Online First: 09 February 2017

[39]. Jiang X, Trouw LA, van Wesemael TJ et al (2014) Anti-CarP antibodiesin two large cohorts of patients with rheumatoid arthritis andtheir relationship to genetic risk factors, cigarette smoking and otherautoantibodies. Ann Rheum Dis 73(10):1761–1768. doi:10.1136/annrheumdis-2013-205109

[40]. Ajeganova S, van Steenbergen HW, Verheul MK et al (2017) Theassociation between anti-carbamylated protein (anti-CarP) antibodiesand radiographic progression in early rheumatoid arthritis: astudy exploring replication and the added value to ACPA and rheumatoidfactor. Ann Rheum Dis 76(1):112–118. doi:10.1136/annrheumdis-2015-208870

[41]. Simon GM, Cheng J, Gordon JI (2012) Quantitative assessment ofthe impact of the gut microbiota on lysine epsilon-acetylation ofhost proteins using gnotobiotic mice. Proc Natl Acad Sci USA109(28):11133–11138. doi:10.1073/pnas.1208669109

[42]. Rantapaa-Dahlqvist S, de Jong BA, Berglin E et al (2003)Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. ArthritisRheum 48(10):2741–2749. doi:10.1002/art.11223

[43]. Nielen MM, van Schaardenburg D, Reesink HW et al (2004)Specific autoantibodies precede the symptoms of rheumatoid arthritis:a study of serial measurements in blood donors. ArthritisRheum 50(2):380–386. doi:10.1002/art.20018

[44]. Shi J, van de Stadt LA, LevarhtEWet al (2014) Anti-carbamylatedprotein (anti-CarP) antibodies precede the onset of rheumatoid arthritis.Ann Rheum Dis 73(4):780–783. doi:10.1136/annrheumdis-2013-204154

[45]. van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A et al(2010) Epitope spreading of the anti-citrullinated protein antibodyresponse occurs before disease onset and is associated with thedisease course of early arthritis. Ann Rheum Dis 69(8):1554–1561. doi:10.1136/ard.2009.124537

[46]. Gagliardi AC, Miname MH, Santos RD: Uric acid: a marker ofincreased cardiovascular risk. Atherosclerosis 2009,202:11-17.

[47]. Goldberg RJ, Burchfiel CM, Benfante R, Chiu D, Reed DM, YanoK: Lifestyle and biologic factors associated with atherosclerоticdisease in middle-aged men. 20-year findings from theHonolulu Heart Program. Arch Intern Med 1995, 155:686-694.

[48]. Fang J, Alderman MH: Serum uric acid and cardiovascular mortalitythe NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey.JAMA 2000, 283:2404-2410.

[49]. Alderman MH, Cohen H, Madhavan S, Kivlighn S: Serum uric acidand cardiovascular events in successfully treated hypertensivepatients. Hypertension 1999, 34:144-150.

[50]. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C,Brunetti P: Relation between serum uric acid and risk of cardiovasculardisease in essential hypertension. The PIUMAstudy. Hypertension 2000, 36:1072-1078.

[51]. Bickel C, Rupprecht HJ, Blankenberg S, Rippin G, Hafner G,Daunhauer A, Hofmann KP, Meyer J: Serum uric acid as an independentpredictor of mortality in patients with angiographicallyproven coronary artery disease. Am J Cardiol2002,89:12-17.

[52]. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL,Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increasesblood pressure in the rat by a novel crystal-independentmechanism. Hypertension 2001, 38:1101-1106.

[53]. Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, HammLL: Childhood uric acid predicts adult blood pressure: theBogalusa Heart Study. Hypertension 2005, 45:34-38.

[54]. Feig DI: Uric acid and hypertension in adolescents. SeminNephrol 2005, 25:32-38.

[55]. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M,Lowe GD: Cardiovascular risk factors, including thromboticvariables, in a population with rheumatoid arthritis. Rheumatology(Oxford) 2001, 40:640-644.
[56]. Erb N, Pace AV, Douglas KM, Banks MJ, Kitas GD: Risk assessmentfor coronary heart disease in rheumatoid arthritis andosteoarthritis. Scand J Rheumatol2004, 33:293-299.
[57]. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV,Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R:Effects of xanthine oxidase inhibition with allopurinol onendothelial function and peripheral blood flow in hyperuricemicpatients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002,105:2619-2624.
[58]. Doehner W, Anker SD: Xanthine oxidase inhibition for chronicheart failure: is allopurinol the next therapeutic advance inheart failure? Heart 2005, 91:707-709.
[59]. Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD:Accelerated atherogenesis in autoimmune rheumatic diseases.Autoimmun Rev 2002, 1:338-347.
[60]. Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM,Frascerra S, Ciociaro D, Ferrannini E: Effect of insulin on renalsodium and uric acid handling in essential hypertension. AmJ Hypertens1996, 9:746-752.
[61]. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, FranekE, Ritz E: Insulin resistance and hyperinsulinemia are alreadypresent in patients with incipient renal disease. Kidney Int1998, 53:1343-1347.
[62]. Kubo M, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Hirakata H,Fujishima M: Effect of hyperinsulinemia on renal function in ageneral Japanese population: the Hisayama study. Kidney Int1999, 55:2450-2456.
[63]. Kato Y, Hayashi M, Ohno Y, Suzawa T, Sasaki T, Saruta T: Mildrenal dysfunction is associated with insulin resistance inchronic glomerulonephritis. Clin Nephrol 2000, 54:366-373.
[64]. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK,He J: Insulin resistance and risk of chronic kidney disease innondiabetic US adults. J Am Soc Nephrol 2003, 14:469-477.
[65]. Peralta CA, Ziv E, Katz R, Reiner A, Burchard EG, Fried L, KwokPY, Psaty B, Shlipak M: African ancestry, socioeconomic status,and kidney function in elderly African Americans: a geneticadmixture analysis. J Am Soc Nephrol 2006, 17:3491-3496.